Overview

Expanded Access to ANG1005 for Individual Patients

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
Details
Lead Sponsor:
Angiochem Inc
Treatments:
Paclitaxel